Biosimilars for Australian Dermatologists

Biosimilars offer the potential for substantial cost savings within the Australian healthcare system. This is particularly salient in dermatology, where biologics are used to treat chronic skin diseases and cost savings will be accrued throughout the life of a patient. However, uptake of biosimilars in clinical practice has been hindered by barriers including insufficient clinician education, concerns about safety and efficacy, and negative patient perception. Increased availability of biosimilars promotes long-term sustainability of the Pharmaceutical Benefits Scheme and may help maintain equitable access to healthcare across Australia.